Thanks to a $1.27 million grant from the United States Department of Defense (DoD), Dr. Katherine Hajjar, a medical professor and clinical investigator with Weill Cornell Medicine can focus investigation now on treatments for proliferative vitreoretinopathy (PVR), a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries during combat. This three-year grant supports investigation into the safety and effectiveness of two novel investigational antibodies. The expert in pediatric hematology-oncology takes on an important mission to help patients that have served their country via the armed forces. Dr. Hajjar ultimately hopes to find a willing pharmaceutical partner to conduct clinical trials should this next research prove successful.
TrialSite provides a brief overview of this important research.
What are the Incidence levels of PVR?
About 200,000 people worldwide each year sustain a penetrating wound to the eye, the main risk factor for PVR. It can also occur in some who undergo complex eye surgeries or experience a detached retina. The condition’s prevalence has risen among military personnel with the increasing use of exp...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).